Zone7 raises $2.5 million seed round to predict injury risk for athletes
Zone7, the company using data and analytics to identify the potential for injuries with athletes, has raised $2.5 million in seed funding.
The company monitors athletes’ performance to determine when they need to be rested to avoid the potential for career-threatening injuries.
The company’s technology has managed to attract investors including Resolute Ventures, UpWest, Amicus Capital, Dave Pell, PLG Ventures, along with athletes like National Basketball Association star Kristaps Porzingis.
Teams in the MLB, La Liga, Champions League, MLS, collegiate athletic departments and Olympic teams are all using the company’s technology, according to a statement.
“Getting injured is one of the worst experiences for any athlete,” said Porzingis, in a statement. “The technology behind Zone7 is extremely impressive and has the potential to change the landscape of sports forever.”
Zone7 uses pattern recognition based on an athlete’s past performance and medical history to determine what course of action is best for the player to ensure that they don’t get hurt. So far, the company says it has achieved a 95 percent accuracy rate when it comes to predicting injuries and reduced the potential for injuries by 75 percent, according to a statement.
“Injuries in professional sports cost billions annually, but in the era of big data it doesn’t have to be that way,” said Tal Brown, co-founder and CEO of Zone7. “Professional sports franchises have massive amounts of untapped health and performance data that, when unlocked by AI, can become one of a team’s most valuable assets. By better understanding every athlete’s breaking points and implementing personalized intervention plans to prevent injuries before they occur, teams no longer have to accept injuries as an inevitability.”
Founded by Tal Brown and Eyal Eliakim, two Israelis who served in the military’s elite technology division called the 8200, Zone7’s executive team has years of experience working with Salesforce on the development of its Einstein product and with professional soccer franchises in Israel.
“Professional sports is, for the most part, slow to embrace medical and performance data, and as such, this has historically been a difficult target market to break into. Tal and Eyal have built a compelling product that is making teams stand up and take notice. It’s literally a game changer,” said Raanan Bar-Cohen, general partner at Resolute Ventures, in a statement. “The fact that Zone7 is the first company to show injuries can be avoided by using artificial intelligence, makes us extremely excited to partner with the Zone7 team.”